Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 3Neoplasms 1Hepatoblastoma 1Fibrolamellar hepatocellular carcinoma 1

Interventions

Bevacizumab 11durvalumab 9atezolizumab 9Specimen Handling 9tremelimumab 8lenvatinib 7Nivolumab 6Magnetic Resonance Spectroscopy 5X-Rays 4Sorafenib 3Oxaliplatin 3Ipilimumab 3Fluorouracil 3tislelizumab 2sapanisertib 2relatlimab 2cabozantinib 2Surgical Procedures, Operative 2Radiation 2Leucovorin 2Immunotherapy 2Immunoglobulin G 2Doxorubicin 2Disulfides 2Carboplatin 2ulixertinib 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1trametinib 1sofosbuvir-velpatasvir drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Sorafenib × 30 days × Clear all
NCT05468359 2026-05-19

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
64 enrolled
Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT03017326 2026-05-13

PHITT

University of Birmingham

Phase 3 Active not recruiting
450 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Hepatoblastoma

NCT01840592 2026-05-06

Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
30 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡